Want to join the conversation?
During 3Q15, $PFE's Global Oncology segment revenues increased 54% YoverY, primarily driven by continued strong momentum following the Feb. 2015 US launch of Ibrance for advanced breast cancer and stronger demand for Sutent, Xalkori and Inlyta in most markets.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.